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Abstract The structure of peptides corresponding to the C-ter-
minal residues from Trypanosoma cruzi (R13), human (H13)
and Leishmania braziliensis (A13) ribosomal proteins were de-
termined using nuclear magnetic resonance. Although there is
only one amino acid di¡erence between them, the peptides
present distinct structures in solution: R13 adopts a random
coil conformation while H13 and A13 form a bend. Interaction
of these peptides with polyclonal antibodies from chronic Cha-
gas’ disease patients and a monoclonal antibody raised against
T. cruzi ribosomal P2L protein was probed by transferred NOE.
The results show that the £exibility of R13 is fundamental for
the binding to the antibody.
, 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Chronic Chagas’ heart disease (cChHD) is the most fre-
quent and severe clinical consequence of infection with Try-
panosoma cruzi [1]. The mechanisms responsible for the car-
diomyopathy are not clearly understood, but the occurrence
of chronic myocardial injury in the near absence of parasites
suggests an autoimmune mechanism [2]. Nevertheless, the hy-
pothesis of an autoimmune disorder in Chagas’ disease re-
mains controversial. Thus, cardiomyopathy might result
from a parasite-induced activation of the immune system lead-
ing to a breakdown of tolerance for self-antigens [3]. Another
possibility involves a T. cruzi-induced cross-reactive immune
response to self-antigens through a molecular mimicry-depen-
dent mechanism [4]. Indeed, immune responses developed
against self-antigens via molecular mimicry-dependent mech-
anisms have been shown to play a role in autoimmune phe-
nomena associated with infectious disease [4^6]. Several
T. cruzi antigens have been reported to present epitopes sim-
ilar to mammalian antigens, including the family of trypomas-
tigote-speci¢c FI-160 antigens [7,8], the microtubule-associ-
ated protein [9], the cardiac myosin antigen (B13) [10], and
members of the ribosomal P protein family [11^13].
Patients with cChHD present a high titer of antibodies
against the C-terminal end of the ribosomal P protein of
T. cruzi, which has high similarity to the C-terminal region
of human ribosomal P proteins and also to the second loop of
the human L-adrenergic [13] and M2 muscarinic receptors
[14]. As the sera of these patients can elicit heart function
disturbances, several researchers believe that the primary se-
quence similarity is related to the observed cross-reactivity of
antibodies from cChHD patients with the heart receptors [14].
In rabbit heart preparations, electrical disturbances can be
alleviated if the patients’ sera are incubated with small pep-
tides corresponding the C-terminal region of the P ribosomal
proteins from humans and T. cruzi, but not from Leishmania
braziliensis [14]. Primary sequence comparison (Table 1)
shows that the three peptides di¡er in only one amino acid,
therefore the A13 result is not compatible with a linear
charged epitope (EEXDDD, R13=E; H13=S; A13=A).
In an e¡ort to understand the structural basis for the cross-
reactivity, we determined the structure of R13, H13 and A13
peptides by nuclear magnetic resonance (NMR) spectroscopy.
Transferred nuclear Overhauser e¡ect spectroscopy (NOESY)
experiments were used to probe interaction and conformation-
al changes upon antibody binding. The results showed di¡er-
ent degrees of £exibility for each peptide and this e¡ect may
result in di¡erent degrees of recognition by antibodies. In that
regard, the tendency of A13 to form a more stable structure in
solution can impair antibody recognition and explain the lack
of inhibition of cChHD patients’ sera by the L. braziliensis-
derived peptide.
2. Materials and methods
2.1. Sample preparation
Sequences of the peptides used for the present study are shown in
Table 1. The ¢rst sequence corresponds to the C-terminus of the
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Table 1
Sequence of peptides derived of ribosomal P protein
Name Sequence number Sequence Origin
R13 107^119 EEEDDDMGFGLFD T. cruzi
H13 102^115 EESDDDMGFGLFD Human
A13 93^105 EEADDDMGFGLFD L. braziliensis*Corresponding author. Fax: (55)-21-25626756.
E-mail address: falmeida@cnrmn.bioqmed.ufrj.br (F.C.L. Almeida).
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T. cruzi P ribosomal protein. H13 is a peptide derived from the hu-
man P ribosomal protein. A13 is derived from the L. braziliensis P
ribosomal protein. All peptides were synthesized by Research Genet-
ics, puri¢ed by high performance liquid chromatography, and checked
by mass spectroscopy.
2.2. Production of the antibodies
The monoclonal antibody (mAb) used was kindly provided by M.J.
Levin. The mAb production and characterization are described in
[15].
We used polyclonal antibodies (pAb), obtained from a group of
cChHD patients, that were previously functionally characterized
[14]. Puri¢cation of the IgG fraction was performed by serum precip-
itation with ammonium sulfate (40%), followed by overnight dialysis
against phosphate bu¡er (pH 8.0) and chromatography in a DEAE
matrix under continuous addition of phosphate bu¡er (pH 8.0).
2.3. Preparation of NMR samples
For NMR experiments the samples were prepared in 10% D2O
(99.9%, Isotec) using 10 mM phosphate bu¡er at pH 5.5. The peptide
concentration was 2 mM for free peptide experiments. The peptide:
pAb molar ratio was 20:1 and the peptide:mAb molar ratio was
100:1 for transfer NOE experiments.
2.4. NMR spectroscopy
The NMR experiments for the free peptides were performed at 5‡C
and 20‡C and experiments for peptides in the presence of antibodies
were conducted at 20‡C. NMR spectra were obtained in a Bruker
Avance DRX600 spectrometer operating at 600.04 MHz. Water sup-
pression was achieved using the WATERGATE technique [16]. Total
correlation spectroscopy (TOCSY) spectra (spin-lock time of 70 ms)
were acquired using the MLEV-17 pulse sequence [17]. NOESY [18]
and transfer NOESY [19] spectra were acquired using a 150 ms mix-
ing time. The spectra were processed using NMRPIPE [20].
In order to establish the fast change between free and bound states
to transfer NOESY experiments we tested di¡erent pH values and
temperatures. This condition occurs in the pH range of 5.5^6.5 and
20‡C. The transfer NOESY experiments required more time acquisi-
tion (about 24 h) due to lower peptide and antibody concentrations.
2.5. NOE data analysis and structure calculation
All NMR spectra were analyzed using NMRVIEW, version 5.0.3
[21]. NOE cross-peaks were integrated in the NOESY spectra and
their intensities were converted to distances, which were calibrated
using the equations suggested by Hybert et al. [22]. The structure
calculations were performed using CNS_Solve version 1.1 [23]. Start-
ing with the extended structure, 100 structures were generated using
the torsion angle simulated annealing protocol [24]. This was followed
by 10 000 steps of simulated annealing at 5000 K and a subsequent
decrease in the temperature in 20 000 steps in the ¢rst slow-cool an-
nealing stage. All the structures were analyzed with the program
MOLMOL [25].
3. Results
3.1. Chemical shift and restraint assignments
The chemical shift assignments of the peptides were per-
Fig. 1. Amide region of 1H NMR spectra of R13 in phosphate bu¡er. a: NOESY spectrum at 5‡C of 2 mM R13, 80 scans. b: NOESY spec-
trum at 20‡C of 2 mM R13, 80 scans. c: Transfer NOESY spectrum of the mixture of 1 mM R13 and 50 WM pAb at 20‡C, 384 scans.
d: Transfer NOESY spectrum of the mixture of 1 mM R13 and 10 WM mAb at 20‡C, 384 scans.
FEBS 28102 16-2-04 Cyaan Magenta Geel Zwart
M.R. Soares et al./FEBS Letters 560 (2004) 134^140 135
formed through TOCSY and NOESY spectra obtained at 5‡C
(Figs. 1a, 2a and 3a) by the sequential strategy as proposed by
Wu«thrich [26]. Sequential connectivities could be observed
through dKNðiþ1Þ, dLNðiþ1Þ and dNNðiþ1Þ NOEs.
The mixing time of 150 ms was used after a NOE buildup
analysis (not shown). At this mixing time there is no spin
di¡usion.
All peptides showed very poor NOESY spectra at 20‡C
(Figs. 1b, 2b and 3b). There could be two causes for that:
one is because of the tumbling rate of the peptide that gen-
erates NOEs with near zero intensity; the other is because the
peptide could be very £exible in solution not showing sequen-
tial NOEs. We observed that for all three peptides at 20‡C the
intra-residue NOEs could be observed at mixing times higher
that 300 ms. When we dropped the temperature to 5‡C we
were able to detect several NOE cross-peaks, both short-range
or long-range. The low temperature could be stabilizing some
structure and/or decreasing the tumbling rate, making non-
zero NOEs.
All three peptides displayed dispersed peaks with sharp
lines, compatible with the small molecular mass (V1.3 kDa)
and high water solubility. Table 2 summarizes the observed
structural features of the peptides in solution. The total num-
ber of assigned NOEs varied among 103 to 127. Most of the
NOEs were intra-residue and sequential. Peptide R13 did not
show any long-range NOE (more than four residues apart)
and only two medium-range NOEs, suggesting that this pep-
tide behaves as a random coil in solution, not showing any
structural tendency.
Peptide H13, on the other hand, showed 15 medium- and
long-range NOEs. The important constraints to de¢ne a struc-
tural tendency are listed in Table 2. Peptide A13 also showed
nine medium- and long-range NOEs. A well-de¢ned structural
tendency could also be noted for both A13 and H13 (Table 2).
3.2. Structure calculation
The structure calculation was performed using distance re-
straints obtained from NOE spectra at 5‡C (Table 2). Struc-
tural statistics of the 20 lowest energies are also shown in
Table 2. The program Procheck_NMR [27] was used for val-
idating the geometries of the structures. Ramachandran plots
[28] show that the majority of the dihedral angles are in the
allowed region (s 91% in favored regions).
RMSD values are also compatible with £exible topologies.
However, there are noticeable di¡erences between R13, H13
and A13. For R13 there is no convergence after structural
calculation (Table 2). This is not surprising since we expected
peptide R13 to be in random coil conformation.
Fig. 2. Amide region of 1H NMR spectra of H13 in phosphate bu¡er. a: NOESY spectrum at 5‡C of 2 mM H13, 80 scans. b: NOESY spec-
trum at 20‡C of 2 mM H13, 80 scans. c: Transfer NOESY spectrum of the mixture of 1 mM H13 and 50 WM pAb at 20‡C, 384 scans.
d: Transfer NOESY spectrum of the mixture of 1 mM H13 and 10 WM mAb at 20‡C, 384 scans.
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For peptides H13 and A13 we were able to calculate well-
de¢ned structures. Fig. 4 shows the 20 lowest energy struc-
tures obtained for the peptides H13 and A13. In both H13
and A13 structures, we observed a hydrophobic core formed
by Met7, Phe9, Leu11 and Phe12. This hydrophobic core is
not stable in R13 probably due to the presence of the negative
residue Glu3 that increases electrostatic repulsion and leads
the peptides to a random coil conformation. Ala3/Ser3 (A13
and H13 respectively) are in close proximity to the hydropho-
bic core, contributing to its stabilization. For peptide A13,
Ala3 is interacting with Phe12 by hydrophobic interaction,
while for peptide H13, Ser3 is interacting with the side chain
of Met7, possibly by hydrogen bond.
The presence of the hydrophobic core leads to a bend of the
Fig. 3. Amide region of 1H NMR spectra of A13 in phosphate bu¡er. a: NOESY spectrum at 5‡C of 2 mM A13, 80 scans. b: NOESY spec-
trum at 20‡C of 2 mM A13, 80 scans. c: Transfer NOESY spectrum of the mixture of 1 mM A13 and 50 WM pAb at 20‡C, 384 scans.
d: Transfer NOESY spectrum of the mixture of 1 mM A13 and 10 WM mAb at 20‡C, 384 scans.
Table 2
Summary of structural statistics for free peptides in phosphate bu¡er at 5‡C
R13 H13 A13
Total number of distance constraints 109 127 103
Number of intra-residue constraints 82 74 67
Number of sequential and medium-range constraints (9 i,i+3) 27 51 33
Number of long-range constraints (v i,i+4) 0 2 3
S3(HN)-M7(HL) F9(HL)-D13-(HL)
D5(HN)-L11(HN) FM7(HL)-F12(HN)
A3(HL)-F12(HN)
Overall energy (kcal/mol) ^ 80.8V 18.3 92.6V 10.1
Pairwise RMSD (AW ) of the residues 2^12a
Backbone 1.38 0.63 0.49
Heavy atoms 1.98 0.94 0.76
% of the residues in favored region of the Ramachandran plotb 91.1 99.4 100
aRMSD values from MOLMOL [24].
bData from PROCHECK [29].
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peptides H13 and A13, where Asp4, Asp5 and Asp6 are the
hinge region. The 20 models of lowest energy present a good
overlap, especially in the bend region.
3.3. Transfer NOESY
Transferred NOE experiments were performed using IgG
puri¢ed from cChHD patients’ sera and a monoclonal IgG
obtained against T. cruzi ribosomal P protein. We investigated
conformational di¡erences between the three peptides in free
and bound states at 20‡C. We used the ratio 1:20 for the pAb
and 1:100 for the mAb.
The addition of the pAb (1:20) at pH 7.0 broadened the
resonances of the peptides. This is due to the binding process.
We then decreased the pH to 6 and 5. The lines sharpened
progressively. We chose to work at pH 6.0 because of the
sharp lines and appearance of several cross-peaks in the NO-
ESY in the presence of the pAb (Figs. 1c, 2c and 3c) spectra,
when compared to the NOESY spectra of the peptides free in
solution at the same conditions (Figs. 1b, 2b and 3b).
At pH 6.0 and 20‡C the peptide/antibody complex achieved
a fast exchange regime. The appearance of NOEs is good
evidence of binding, because of the decrease in the tumbling
rate, making the peptides behave as a larger protein.
None of the medium- and/or long-range NOEs that de¢ne
the structure calculated in aqueous solution at 5‡C (Fig. 4)
could be observed in the transfer NOESY experiments (Figs.
1c, 2c and 3c). The absence of these NOEs, however, is not
due to the lower peptide concentration in the experiments in
the presence of antibody, since the number of scans was al-
most ¢ve times higher in the presence of antibody while the
concentration is halved. This suggests that the structure
(bend) obtained for the peptides A13 and H13 was disrupted
upon binding with the antibody. The conformation in the
presence of antibody could not be determined because of
the lack of long-range NOEs. This may imply that under these
conditions the peptides assume an extended conformation.
A de¢ned extended conformation in the presence of anti-
body is corroborated by the presence of sharp lines and some
intra-residue NOEs, mostly connecting adjacent residues (KN,
i,i+1). The presence of intra-residue NOEs for most of the
amino acid sequence, from 3 to 12, is also noteworthy.
The interaction of the peptides with the mAb was limited by
the amount of antibody. However, the number of NOEs ob-
served in the transfer NOESY spectra of peptides R13, H13
and A13 (Figs. 1d, 2d and 3d) correlates with the binding
ability. Note that peptide A13 does not bind to the mAb,
or binds at low a⁄nity. The number of transfer NOEs for
peptide R13 is higher than for peptide H13.
A similar observation can be made on the interaction with
the pAbs. The number of observed NOEs in the transfer NO-
ESY spectra is bigger for peptide R13 (Fig. 1c) than H13 (Fig.
2c) and A13 (Fig. 3c), in the same order as observed for the
Fig. 4. Twenty lowest energy structures calculated for the peptides in phosphate bu¡er at pH 5.5 and 5‡C (left) and lowest energy structure
(right). a: H13. b: A13.
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interaction with the mAb: R13sH13sA13. This order is
inverse when compared with the presence of structure of the
free peptides in solution. A13 shows better resolution in the
backbone than H13, while R13 does not show any structural
tendency. The rationale is that the presence of structure in the
free state leads to a decrease in the binding a⁄nity.
The fact that peptide A13 does not interact with the mAb is
in accordance with the work of Mahler et al. [15]. In this
work, the authors tested the importance of each amino acid
in the mAb recognition by alanine mutation scanning. They
concluded that the amino acids essential for recognition were
Glu3, Asp5, Asp6, Gly8 and Phe9.
4. Discussion
Peptides that correspond to epitope regions of proteins are
widely used as synthetic antigens, vaccines or diagnostic re-
agents. They have been extensively studied to understand their
antigenicity and immunogenicity in an e¡ort to develop e¡ec-
tive new chemotherapeutic drugs and vaccines. Although sim-
ple models, they are not completely understood. Epitopes are
usually classi¢ed as linear or conformational depending on
requirements for antibody recognition.
In the present work, we describe the solution structure of
three peptides: R13, H13 and A13. They represent the epitope
regions of ribosomal P proteins that seem to be responsible
for autoimmune responses observed in cChHD patients.
There is only one amino acid di¡erence between them. This
di¡erence could be considered innocuous for a given linear
epitope, since the major feature of the epitope is maintained,
the negative charge. But several results show di¡erences in
antibody recognition between them [14,15].
Using this simple model we decided to investigate what
could be structurally responsible for the observed di¡erences.
The peptides were studied in the free and antibody-bound
state. Peptides are known to be £exible in solution due to
the lack of long-range interaction. NMR studies are then suit-
able to monitor the behavior in solution.
We investigated the structure at 5‡C and the obtained NO-
ESY spectra permitted structural calculations. Peptide R13 is
in random coil conformation. Peptides H13 and A13 showed
well-de¢ned structures in solution. Change of only one amino
(residue 3) acid residue is enough to modify the peptide struc-
ture in solution. Both peptides formed a bend stabilized by
interactions in which residue 3 participates (Ser3 and Ala3).
The addition of antibody (50 WM pAb and 10 WM mAb) in
usual conditions (pH 7.0) creates line broadening in the pep-
tide spectra, indicating an e¡ective binding with antibodies.
This line broadening re£ects the slow exchange between the
bound and free peptide states. A decrease in pH makes the
line narrow, indicating a fast exchange between the bound
and free peptide states. This condition is appropriate to trans-
fer NOE experiments. Then, the transfer NOESY experiments
were carried out at 20‡C and the results were good quality
spectra with several correlation peaks. The observed NOEs
were exclusively from the bound state since the spectra of
the peptides free in solution do not show NOEs at this tem-
perature (20‡C).
The spectra present some correlation peaks, including inter-
residuals. This indicates that the presence of antibody reduces
the peptide £exibility at 20‡C probably inducing a more de-
¢ned conformation. The absence of long-range correlation
indicates an extended conformation for these peptides in the
bound state.
Various antibody^epitope complexes are formed with pep-
tides in extended conformation, for example, the region be-
tween residues 101^108 of in£uenza hemagglutinin complexed
with its antibody [29] and the peptide corresponding to resi-
dues 308^333 of the HIV Gp120 with IgG Fab [30].
These observations suggest that for the pAb recognition
speci¢c folding is not necessary.
Due to the fact that the peptide^antibody does not require
a speci¢c conformation for the peptide, the possibility of the
existence of cross-reaction is increased. Then, considering that
for an autoimmune process a cross-reaction is necessary, our
¢ndings favor this hypothesis.
Our data indicate that the binding of R13 is more e⁄cient
because it is a random coil in solution whereas R13 and A13
do not bind so e⁄ciently because they show a structural ten-
dency free in solution, with a conformation di¡erent from the
bound state. There is an increasing notion in the literature
that the pre-existence of the bound conformation in the free
state is fundamental for binding [31]. In the present work we
have strong evidence that conformational states are impor-
tant, although we could not rule out the direct in£uence of
the amino acid change in the peptides in the a⁄nity to the
antibody.
5. Notes
The coordinates were deposited in the Protein Data Bank
with the following codes: 1S4H and 1S4J. The chemical shift
assignment tables were deposited in the Biomagnetic Reso-
nance Data Bank.
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